This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.
REGN vs. INCY: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.
Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.
RAPT Reports Positive Data From Atopic Dermatitis Study
by Zacks Equity Research
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19
by Zacks Equity Research
AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
by Zacks Equity Research
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
REGN vs. INCY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
by Zacks Equity Research
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Company News for Jun 7, 2021
by Zacks Equity Research
Companies in the news are: REGN, CHRS, SENS, CGEM
Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?
by Zacks Equity Research
Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.
Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment
by Zacks Equity Research
Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.